カルバマゼピン錠１００ｍｇ「アメル」
基本情報
| 項目 | 値 |
|---|---|
| DrugBank ID | DB00564 |
| エビデンスレベル | L5（計算予測のみ） |
| 予測適応症数 | 69 |
| 日本商品名（例） | カルバマゼピン錠１００ｍｇ「アメル」, カルバマゼピン錠１００ｍｇ「フジナガ」, カルバマゼピン錠２００ｍｇ「アメル」 |
承認適応症（KEGG）
躁病, 躁うつ病の躁状態、統合失調症、三叉神経痛
予測適応症（TxGNN）
以下は TxGNN モデルにより予測された潜在的新適応症です。スコアが高いほど関連性が高いと予測されています。
| # | 適応症 | スコア | ソース |
|---|---|---|---|
| 1 | glossopharyngeal motor neuropathy | 99% | DL |
| 2 | trigeminal nerve neoplasm | 99% | DL |
| 3 | trigeminal neuralgia | 99% | DL |
| 4 | visual epilepsy | 99% | DL |
| 5 | startle epilepsy | 99% | DL |
| 6 | thinking seizures | 99% | DL |
| 7 | orgasm-induced seizures | 99% | DL |
| 8 | eating seizures | 99% | DL |
| 9 | micturation-induced seizures | 99% | DL |
| 10 | audiogenic seizures | 99% | DL |
| 11 | reading seizures | 99% | DL |
| 12 | beta-ketothiolase deficiency | 99% | DL |
| 13 | Rett syndrome, congenital variant | 99% | DL |
| 14 | 14q12 microdeletion syndrome | 99% | DL |
| 15 | status epilepticus | 99% | DL |
| 16 | partial epilepsy | 99% | DL |
| 17 | partial motor epilepsy | 99% | DL |
| 18 | epilepsy with generalized tonic-clonic seizures | 99% | DL |
| 19 | adolescent/adult onset autosomal dominant epilepsy with auditory features | 99% | DL |
| 20 | facial neuralgia | 99% | DL |
| 21 | guanidinoacetate methyltransferase deficiency | 99% | DL |
| 22 | combined hyperactive dysfunction syndrome of the cranial nerves | 99% | DL |
| 23 | epilepsy | 99% | DL |
| 24 | glossopharyngeal nerve neoplasm | 99% | DL |
| 25 | vagus nerve disease | 99% | DL |
| 26 | glossopharyngeal nerve paralysis | 99% | DL |
| 27 | Lennox-Gastaut syndrome | 98% | DL |
| 28 | cutis verticis gyrata | 98% | DL |
| 29 | trichotillomania | 98% | DL |
| 30 | myoclonic-atonic epilepsy | 98% | DL |
| 31 | Tourette syndrome | 98% | DL |
| 32 | febrile infection-related epilepsy syndrome | 98% | DL |
| 33 | photosensitive occipital lobe epilepsy | 98% | DL |
| 34 | cryptogenic late-onset epileptic spasms | 98% | DL |
| 35 | atypical childhood epilepsy with centrotemporal spikes | 98% | DL |
| 36 | perioral myoclonia with absences | 98% | DL |
| 37 | restless legs syndrome | 98% | DL |
| 38 | electroclinical syndrome | 97% | DL |
| 39 | nicotine dependence | 97% | DL |
| 40 | methemoglobinemia, alpha type | 97% | DL |
| 41 | idiopathic neonatal atrial flutter | 96% | DL |
| 42 | attention deficit-hyperactivity disorder | 96% | DL |
| 43 | early onset absence epilepsy | 96% | DL |
| 44 | methemoglobin reductase deficiency | 96% | DL |
| 45 | myofascial pain syndrome | 95% | DL |
| 46 | asperger syndrome, susceptibility to | 95% | DL |
| 47 | gaze palsy, familial horizontal, with progressive scoliosis | 95% | DL |
| 48 | multifocal atrial tachycardia (disease) | 95% | DL |
| 49 | childhood onset epileptic encephalopathy | 95% | DL |
| 50 | autism susceptibility 1 | 94% | DL |
（上位50件を表示。全69件の予測があります）
免責事項
これらの予測は研究目的のみであり、医療アドバイスを構成するものではありません。 臨床応用には必ず適切な検証が必要です。